ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,282.40
1.44%
Dow Jones
40,421.36
0.33%
Brent Oil
81.62
-0.80%
Bitcoin
68,003.75
-0.22%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateTimeSourceHeadlineSymbolCompany
06/25/20248:00AMPR Newswire (US)Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal StudyNASDAQ:LPCNLipocine Inc
06/10/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/10/20248:00AMPR Newswire (US)Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024NASDAQ:LPCNLipocine Inc
06/07/20245:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20245:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20245:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20245:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20245:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/05/20244:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/03/20245:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/03/20245:09PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LPCNLipocine Inc
05/09/20248:00AMPR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
05/09/20246:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
05/09/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/08/20248:00AMPR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
05/08/20246:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/01/20248:00AMPR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
04/11/20247:00AMPR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
03/28/20248:00AMPR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
03/25/20248:00AMPR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
03/07/20245:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20248:00AMPR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
03/07/20246:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20246:07AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
03/06/20248:00AMPR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
03/06/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/12/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/06/20248:00AMPR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/20248:00AMPR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
01/18/20248:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Your Recent History

USOTC
IDVV
International Endeavors (PK)
USOTC
ITUP
Interups (CE)
USOTC
MGON
Megola (PK)
NYSE
AMC
AMC Entertainment
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
GRLT
Grillit (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
CNNA
Cann American (CE)
USOTC
NBRI
North Bay Resources (PK)
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
SHMP
NaturalShrimp (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved